How IBD Is Monitored Between Flares: Blood Markers, Stool Tests and Scopes

The envelope from the lab arrives on a Tuesday, and it lands on the kitchen counter next to a half-eaten bowl of oatmeal. The person opening it feels fine. No cramping for months, no rushing to the bathroom, energy back to something like normal. So why does the letter ask for another stool sample, and why is a colonoscopy penciled in for the fall?

That quiet mismatch, between feeling well and still being checked, is the heart of living with Crohn’s disease or ulcerative colitis. IBD monitoring blood tests, stool markers and scopes exist because the gut can be inflamed while the person it belongs to feels ordinary. Inflammation that simmers unnoticed is what scars bowel, narrows it, and raises long-term cancer risk in the colon.

This explainer walks through what each test measures, what it misses, how often the checks tend to happen, and which results actually change decisions. It is written for the person holding that envelope.

What does IBD monitoring actually track between flares?

Inflammatory bowel disease, or IBD, is the umbrella term for two long-term conditions in which the immune system drives inflammation in the digestive tract: Crohn’s disease, which can affect any part of the gut from mouth to anus, and ulcerative colitis, which is confined to the colon and rectum. Both come and go in waves. A flare is a period when inflammation and symptoms rise; remission is a period when they settle.

Monitoring between flares tracks three separate things, and it helps to keep them apart in your head.

The first is inflammation itself. Symptoms are a poor proxy. People can pass formed stools and still have ulcers visible on a scope, and, in the other direction, people can have loose stools from irritable bowel syndrome or bile acid problems while their colon lining is perfectly healed. The Mayo Clinic’s overview of IBD diagnosis makes the point that lab tests and endoscopy are used to look for inflammation regardless of how the person feels.

The second is complications. Long-standing inflammation can cause anemia from slow blood loss, poor absorption of iron, vitamin B12 and vitamin D, strictures (narrowed segments of bowel), fistulas (abnormal tunnels between bowel and other organs), and, in the colon, a gradual rise in the risk of precancerous cell changes called dysplasia.

The third is the medicines. Many IBD treatments dampen the immune system, and some can affect blood counts, liver enzymes or infection risk. Routine bloods check that the treatment is not quietly causing harm.

Put those three together and the pattern of tests starts to make sense: a blood draw looks mostly at complications and drug safety, a stool test looks at inflammation, and a scope confirms what the lining really looks like.

What are IBD monitoring blood tests looking for?

A typical monitoring panel reads like a list of abbreviations, so here is the plain version of what each one means.

C-reactive protein (CRP) is a protein the liver releases into the blood within hours of inflammation anywhere in the body. MedlinePlus describes it as a general inflammation marker, not a gut-specific one: a chest infection or a sprained ankle can raise it just as a Crohn’s flare can.

Erythrocyte sedimentation rate (ESR) measures how quickly red blood cells settle in a tube, which speeds up when inflammatory proteins are present. It responds more slowly than CRP and takes longer to fall once inflammation resolves.

Full blood count reports hemoglobin (low readings suggest anemia), platelets (often raised in active inflammation), and white blood cells (raised in inflammation or infection, but sometimes lowered by immune-suppressing medicines).

Ferritin, iron studies, vitamin B12 and folate pick up the nutritional deficiencies that inflamed or surgically shortened bowel struggles to absorb. Ferritin is tricky: it stores iron, but it also rises with inflammation, so a normal ferritin during a flare can hide iron deficiency.

Albumin is the main protein in blood. It drops when inflammation is severe or protein is being lost through an ulcerated gut wall.

Liver and kidney tests are usually there for drug safety rather than for the IBD itself.

Notice what is missing. There is no blood test that says “the colon is inflamed” the way a stool marker or a scope can. Blood readings are downstream signals, useful for trends and for complications, and the NHS notes they are part of the picture rather than the whole of it.

What are the four inflammatory markers people ask about?

Search engines are full of the phrase “the four inflammatory markers,” but there is no official list of four in any IBD guideline. What the phrase usually means, in a gut clinic, is the cluster of results a doctor scans first when judging whether inflammation is active: CRP, ESR, platelet count and white cell count. Some clinicians would swap in albumin, and almost all would add fecal calprotectin, which is a stool test rather than a blood test.

Each one moves on its own clock, and that matters for interpretation.

CRP is the sprinter. Levels can climb within about six to twelve hours of an inflammatory trigger and can fall back within days once the trigger stops, which is why MedlinePlus describes it as useful for tracking response to treatment. A CRP that was high last month and is normal now is a genuinely encouraging trend.

ESR is the marathon runner. It rises over days and drifts down over weeks, so it lags behind the real state of the bowel. It is also nudged upward by anemia, pregnancy and older age, none of which have anything to do with IBD activity.

Platelets and white cells are less specific still. Platelets climb with inflammation and with iron deficiency; white cells rise with infection and with steroid use, and fall with some immunomodulator medicines.

The honest summary: these markers are supportive evidence, not verdicts. A doctor who sees CRP, ESR and platelets all climbing in the same direction will take it seriously. A doctor who sees a single borderline value will usually repeat it, or reach for a stool test, before changing anything.

Why IBD monitoring blood tests alone can miss a flare

Here is a fact that surprises many people with Crohn’s disease: a normal CRP does not prove the gut is calm.

A sizeable minority of people simply do not mount a CRP response even when a scope shows clear ulceration. The reasons are partly genetic (variation in the gene that codes for CRP), partly anatomical (inflammation limited to the rectum or a short segment of small bowel often fails to spill enough signal into the bloodstream), and partly about depth (superficial inflammation in ulcerative colitis raises CRP less reliably than the deep, full-thickness inflammation typical of Crohn’s). The international STRIDE-II consensus, published in Gastroenterology in 2021, treats CRP normalization as an intermediate target precisely because it is helpful when it moves but not sufficient on its own.

Blood tests also miss things that are not inflammation but still matter. A stricture, a narrowed scarred segment left behind by earlier damage, can cause cramping and bloating with a perfectly normal blood panel, because scar tissue is not inflamed. Only imaging or a scope will show it.

The reverse error is just as common. CRP climbs with a dental abscess, a urinary infection, or the flu. Someone who feels rough and sees a raised CRP may assume the IBD is flaring when the real cause is elsewhere. Acting on that assumption could mean an unnecessary steroid course.

This is why guideline-based monitoring layers tests rather than relying on one. Blood gives the trend and flags complications. Stool calprotectin gives a gut-specific reading. Endoscopy or imaging gives the ground truth. When the three agree, decisions are straightforward. When they disagree, the disagreement itself is information, and it usually prompts a closer look rather than a guess.

What causes high fecal calprotectin levels, and is IBD the only cause?

Calprotectin is a protein packed inside neutrophils, the white blood cells that flood into inflamed tissue. When the gut lining is inflamed, neutrophils migrate into the bowel wall and are shed into the stool, carrying calprotectin with them. A fecal calprotectin test measures how much of that protein is present per gram of stool. More protein means more neutrophils, which means more inflammation in the gut specifically.

People often type “what autoimmune disease causes high calprotectin” into a search bar. The answer needs one correction: IBD is the chronic condition most strongly associated with raised calprotectin, but it is classified as an immune-mediated disease rather than a classic autoimmune one, because no single self-target antibody drives it the way it does in, say, celiac disease or type 1 diabetes.

Calprotectin is a marker of gut inflammation, not a marker of IBD. Other causes of a raised result include gut infections (bacterial and viral), regular use of non-steroidal anti-inflammatory painkillers, colorectal polyps or cancer, diverticulitis, and microscopic colitis. Irritable bowel syndrome, by contrast, does not raise calprotectin, which is why the test is so useful for telling IBS-type symptoms apart from an IBD flare without a scope.

Values come with caveats. Laboratories differ in their reference ranges and in the assay used, so a number from one lab is not directly comparable with a number from another. STRIDE-II sets a target range of roughly 100 to 250 micrograms per gram for treat-to-target monitoring, while acknowledging that many labs consider readings under about 50 normal. Day-to-day variation is real; a single mildly raised result is usually repeated before anything changes. A first-morning sample tends to be more consistent than one collected later in the day.

Blood tests vs stool tests vs scopes: how the three compare

No single test does everything. The table below summarizes what each one is good at and where it falls short, drawing on the Mayo Clinic and NHS descriptions of IBD diagnosis and monitoring and on the STRIDE-II framework.

Test	What it measures	Strengths	Limitations
Blood panel (CRP, ESR, full blood count, albumin, iron studies)	Whole-body inflammation, anemia, nutrition, drug safety	Quick, widely available, tracks trends and complications	Not gut-specific; a meaningful share of people never raise CRP despite active disease
Fecal calprotectin	Neutrophils shed into stool from the gut lining	Gut-specific, non-invasive, correlates with what a scope would show	Raised by infection, painkillers, polyps; lab ranges vary; single results fluctuate
Colonoscopy or sigmoidoscopy	Direct view of the lining, with biopsies	Reference standard; detects dysplasia; confirms healing	Needs bowel preparation and sedation; small risk of bleeding or perforation; cannot see most of the small bowel
Imaging (MRI or CT enterography, intestinal ultrasound)	Bowel wall thickness, strictures, fistulas, small bowel	Sees beyond the reach of a scope; ultrasound is radiation-free and can be done in clinic	Less detail of the surface lining; availability of skilled ultrasound varies

Reading down the columns, a pattern emerges. Blood tests are cheap on effort but poor on specificity. Calprotectin is the workhorse for deciding whether a scope is needed at all. The scope is the arbiter but is used sparingly because of the preparation and small risks involved. Imaging fills in the small bowel and the deeper layers of the wall that a camera cannot see.

Most services use them in that order: bloods and calprotectin routinely, a scope when the non-invasive results are unclear, worrying, or when surveillance for precancerous change is due.

Who is monitored closely, and who is usually asked to wait?

Monitoring intensity is not one-size-fits-all. It is scaled to how likely inflammation is to be hiding and how much damage it could do if it were.

People usually monitored more closely include anyone newly diagnosed, because the first year or two reveal how the disease behaves; anyone within a few months of a flare or a treatment change, when the question “is this working?” is still open; people with extensive ulcerative colitis or colonic Crohn’s disease, because the cancer surveillance clock starts after roughly eight to ten years of disease, according to guidance summarized by the Mayo Clinic and the NHS; people who also have primary sclerosing cholangitis, a liver condition that sharply raises colon cancer risk and usually brings forward and tightens surveillance; anyone with a previous finding of dysplasia; and children and adolescents, in whom growth and nutrition add extra markers to watch.

People often asked to wait, meaning monitored less often or with fewer tests, include those in stable, long-term remission on unchanged treatment with a recent clean scope, and those with disease limited to the rectum, for whom routine cancer surveillance is generally not recommended because the risk is close to that of the general population.

“Wait” has a second meaning too. During a severe flare, particularly acute severe ulcerative colitis, a full colonoscopy carries a higher risk of perforation, and teams usually prefer a limited sigmoidoscopy or imaging until things settle. Similarly, a calprotectin taken during a gut infection will be uninterpretable, so it is often deferred until the infection clears.

The decision about where any individual sits on this spectrum belongs to the treating team, who weigh disease extent, history, current medicines and personal preference together.

What actually happens at a monitoring colonoscopy?

A colonoscopy is an examination in which a flexible tube with a camera at its tip is passed through the anus around the full length of the colon. For IBD monitoring it does two jobs: it shows whether the lining has healed, and, in longer-standing colitis, it hunts for dysplasia.

The day before, you follow a low-residue diet and drink a bowel preparation solution that clears the colon. This part is universally disliked and genuinely matters: a poorly cleared colon hides the flat, subtle changes surveillance is looking for. On the day, most people receive sedation. According to the Cleveland Clinic, the procedure itself typically takes 30 to 60 minutes, and you will need someone to take you home.

During the scope, the doctor examines each segment and takes biopsies, tiny pinches of tissue, even if the lining looks normal. Microscopic inflammation can persist when the surface looks healed, and histological remission (a normal biopsy under the microscope) is increasingly discussed as a deeper level of control. For surveillance, many services use chromoendoscopy, in which a dye is sprayed onto the lining to make subtle irregularities stand out.

Risks are low but real. Bleeding after biopsy is usually minor and self-limiting. Perforation, a tear in the bowel wall, is uncommon and is the main reason scopes are avoided during severe flares. Sedation carries its own small risks, which the team will discuss beforehand.

Alternatives depend on the question. A flexible sigmoidoscopy examines only the left side of the colon, needs less preparation, and is often enough to confirm a suspected flare in ulcerative colitis. For Crohn’s disease in the small bowel, MRI enterography, CT enterography, capsule endoscopy (a swallowed camera) or intestinal ultrasound may be chosen instead, since a colonoscope reaches only the last few centimeters of small intestine.

What is treat-to-target, and why does mucosal healing matter?

For decades, IBD care aimed at one thing: make the symptoms stop. If you felt well, the treatment was judged a success. The problem, revealed as scoping became routine, was that plenty of people who felt well still had inflamed bowel, and those people went on to develop strictures, surgery and hospital admissions at higher rates than people whose lining had actually healed.

Treat-to-target is the response to that discovery. Instead of steering by symptoms alone, the care team agrees a set of measurable goals and checks progress against them at set intervals, adjusting treatment if a target is missed. STRIDE-II, the international consensus published in 2021, lays these out in tiers.

Short-term targets are clinical response, meaning a meaningful drop in symptoms, and then clinical remission, meaning symptoms have largely resolved. Intermediate targets are normalization of CRP, a drop in fecal calprotectin into the target range, and, in children, restoration of normal growth. The long-term targets are endoscopic healing, absence of disability, and normal quality of life. Histological healing in ulcerative colitis and transmural healing (healing through the full thickness of the wall, seen on imaging) in Crohn’s disease are described as adjuncts rather than formal targets, because the evidence for aiming at them is still maturing.

Mucosal healing, the term for a lining that looks intact on a scope, sits at the center of this because it is the outcome most consistently linked to fewer flares, fewer hospital admissions and less surgery in observational studies. It is not a guarantee of anything, and STRIDE-II is careful to describe it as a target rather than a promise.

What this means for the person being monitored is simple: a test that comes back abnormal while you feel fine is not a false alarm. It is the system doing exactly what it was designed to do, catching inflammation before it becomes damage.

How are IBD medicines themselves monitored with blood tests?

A good share of routine IBD bloodwork has nothing to do with the bowel. It is there to make sure the medicines are not causing harm, and the pattern of tests depends on the class of medicine, not the person.

Thiopurines, an older class of immunomodulators, work by dampening the production of rapidly dividing immune cells. That same action can suppress the bone marrow, lowering white cells and platelets, and can strain the liver. Regular full blood counts and liver tests are standard for as long as someone takes them, more frequently at the start and at any change in dose, then settling into a routine rhythm set by the prescriber. Before starting, many teams check an enzyme called TPMT, which affects how quickly the medicine is broken down.

Methotrexate, another immunomodulator, carries liver and blood count monitoring for similar reasons.

Biologic medicines are antibodies given by injection or infusion that block specific inflammatory signals; anti-TNF agents are the longest established. Two blood-based checks are common. Before starting, screening for latent tuberculosis and hepatitis B is routine, because suppressing the immune system can reactivate dormant infection. During treatment, some teams measure the level of the medicine in the blood and check for antibodies the body may have made against it, a practice called therapeutic drug monitoring. Low levels or high antibodies can explain a loss of response and help the prescriber decide between adjusting, switching or adding treatment.

Newer oral small-molecule medicines, including JAK inhibitors, come with their own schedule of blood counts and lipid checks.

None of this should be read as guidance to start, stop or change anything. The purpose here is to explain why the phlebotomist keeps asking for your arm when your gut feels fine: the answer is often the medicine, not the disease.

What the days and weeks after a monitoring round usually look like

Monitoring generates a small waiting game, and knowing the typical timing takes some of the sting out of it.

Routine blood results are usually available to the care team within a day or two. Fecal calprotectin is processed in batches at many laboratories, so results commonly take longer, anything from several days to a couple of weeks depending on the service. Biopsy results from a colonoscopy pass through a pathology laboratory and typically return over one to two weeks. The Cleveland Clinic notes that the doctor may discuss what was seen immediately after the scope, but the microscopic findings come later.

What happens next depends on the pattern.

When everything is quiet (normal bloods, calprotectin in range, a scope that shows healing), the most common outcome is no change at all. The team confirms the current plan and sets the next check. For people in stable remission, the NHS describes ongoing regular reviews, often on a roughly yearly cycle, with tests in between if symptoms return.

When results are borderline, the usual move is a repeat. A single mildly raised calprotectin is frequently rechecked after a few weeks rather than acted on, because of the day-to-day variability described earlier.

When results are clearly abnormal despite good symptoms, the conversation shifts to whether treatment needs adjusting, and often to whether a scope or imaging should confirm what the stool test is suggesting before any change is made. Under a treat-to-target approach, STRIDE-II suggests reassessing calprotectin and CRP within roughly three to six months of any treatment change to see whether the new plan is working.

A practical tip for this stretch: ask how you will receive results and whom to contact if you have not heard within the expected window. Silence is sometimes good news and sometimes a lost letter.

Can you monitor IBD at home? Symptom scores, diaries and home calprotectin

The distance between clinic visits has quietly shrunk over the past decade, thanks to tools that let people report and even test at home.

The simplest is a structured symptom score. Clinicians use short questionnaires such as the Harvey-Bradshaw Index for Crohn’s disease and the Simple Clinical Colitis Activity Index for ulcerative colitis, which convert stool frequency, urgency, bleeding, pain and general wellbeing into a number that can be tracked over time. Several services now offer these through apps or web portals, so a rising score can trigger a call before a routine appointment falls due.

Home fecal calprotectin kits take this a step further. The person collects a stool sample, applies it to a test cassette, and reads the result with a smartphone camera, which transmits it to the clinic. Studies have shown reasonable agreement between home devices and laboratory assays, though the home tests are generally best treated as a triage tool: a clearly low result is reassuring, a clearly high result prompts formal testing, and a middling result needs the laboratory.

Intestinal ultrasound is the newest addition to the toolkit, though it happens in clinic rather than at home. A trained clinician scans the abdomen and measures bowel wall thickness and blood flow in real time, without radiation, preparation or sedation. It is increasingly used in Europe and gaining ground in the United States as a way to check response to treatment within weeks rather than waiting for a scope.

What none of these replace is the periodic scope in long-standing colitis, because dysplasia produces no symptoms and no calprotectin signal. Home tools are excellent at answering “am I inflamed right now?” They cannot answer “has anything precancerous developed?” That question still needs a camera and a biopsy.

What people often get wrong about IBD monitoring

Some misunderstandings come up in almost every clinic, and clearing them away makes the tests easier to live with.

“If I feel fine, I’m in remission.” Clinical remission and endoscopic remission are different things. STRIDE-II exists because the two frequently disagree, and the disagreement predicts future trouble.

“A normal CRP means nothing is going on.” As covered earlier, a meaningful proportion of people with Crohn’s disease, and many with ulcerative colitis limited to the rectum or left colon, never raise CRP during active disease. A normal reading lowers the odds of inflammation; it does not rule it out.

“Calprotectin is a test for IBD.” It is a test for gut inflammation. Infections, painkillers and polyps raise it too, and it is never used alone to make a diagnosis.

“I’ll need a colonoscopy every year for life.” Surveillance intervals are risk-based and range from roughly one to five years, according to guidance summarized by the Mayo Clinic, and they start only after several years of colonic disease. People with disease confined to the rectum are generally not enrolled at all.

“Blood tests will pick up bowel cancer.” They will not, reliably. Anemia can be a clue, but dysplasia and early cancer are found by looking, not by drawing blood.

“Skipping a stool sample when I’m well doesn’t matter.” The whole point of the sample is to catch inflammation before symptoms. Skipping it when well is skipping it at the exact moment it is most useful.

“Calprotectin measures leaky gut.” It does not. It counts neutrophil protein. “Leaky gut” is not a recognized diagnosis, and no validated stool test measures it.

“More tests means the doctor thinks something is wrong.” Usually it means the opposite: the team is trying to keep it that way.

Questions to ask your care team about your monitoring plan

A monitoring plan works best when the person being monitored understands it. These questions tend to surface the information that matters, and none of them should feel awkward to ask.

• Which tests am I having, and what is each one actually checking: inflammation, complications or the medicine?
• What is my personal target? Are we aiming for symptoms alone, a calprotectin range, a CRP, or a healed lining on a scope?
• How often will each test be repeated while I am stable, and what would make you bring one forward?
• When and how will I get my results, and whom do I contact if I have not heard by then?
• What calprotectin range does this laboratory consider normal, and what level would prompt you to act or to repeat the test?
• If my CRP has always been low even during flares, does that change how you interpret my blood results?
• Am I due for cancer surveillance, and if so, when does my personal clock start and how often will I be scoped?
• Which of my medicines need safety bloods, how often, and what would an abnormal result lead to?
• Is intestinal ultrasound, home calprotectin testing or an app-based symptom score available here, and would it suit my situation?
• If a stool test comes back high while I feel well, what happens next: repeat, scope, imaging or a treatment discussion?
• What symptoms should make me call between scheduled checks rather than wait?

Write the answers down, or ask for them in a letter or portal message. Monitoring plans span years, teams change, and a written summary of your own targets and intervals is one of the more useful documents you can carry from one appointment to the next.

When to call your doctor: red-flag signs between scheduled checks

Scheduled monitoring is designed for the quiet stretches. Some symptoms should not wait for the next appointment, and a few need same-day or emergency care.

Contact your care team promptly if you notice a clear return of symptoms that had settled, such as increasing stool frequency, new or increased blood in the stool, night-time bowel movements, persistent abdominal pain, unintended weight loss, or worsening fatigue, particularly if the pattern lasts more than a few days. Also report new joint pain and swelling, painful red eyes, or new skin rashes, which can accompany gut inflammation. Anyone on immune-suppressing treatment should report a fever, a persistent cough, or an infection that is not settling, since these medicines can blunt the usual warning signs.

Seek urgent, same-day assessment, or emergency care, for any of the following: passing blood in large amounts or continuously; six or more bloody stools a day together with fever, a fast heartbeat or feeling faint, a pattern the NHS and other guidance describe as a marker of severe colitis; severe or rapidly worsening abdominal pain with a hard or swollen abdomen; repeated vomiting or inability to keep fluids down; signs of dehydration such as very little urine, dizziness or confusion; yellowing of the skin or eyes; or sudden calf pain and swelling, or breathlessness with chest pain, since active IBD raises the risk of blood clots.

None of these lists is a tool for self-diagnosis. They are prompts to pick up the phone. The treating team will decide whether a symptom warrants a test, a scope, a change in plan or simple reassurance, and they would far rather hear about something that turns out to be minor than miss something that was not.

Frequently asked questions

How does IBD show up in bloodwork?

IBD usually shows up indirectly: raised C-reactive protein and erythrocyte sedimentation rate from inflammation, a high platelet count, low hemoglobin from anemia, low ferritin, B12 or vitamin D from poor absorption, and low albumin when inflammation is severe. None of these is specific to IBD, and some people with active disease have entirely normal bloods, which is why stool calprotectin and endoscopy are used alongside them.

What autoimmune disease causes high calprotectin?

The condition most strongly linked to a high fecal calprotectin is inflammatory bowel disease, meaning Crohn’s disease or ulcerative colitis, although these are classified as immune-mediated rather than strictly autoimmune. Calprotectin is a marker of gut inflammation from any cause, so bowel infections, regular anti-inflammatory painkiller use, polyps, colorectal cancer, diverticulitis and microscopic colitis can also raise it. Irritable bowel syndrome does not.

What are the four inflammatory markers?

There is no official list of four, but the markers a gut clinic scans first are usually C-reactive protein, erythrocyte sedimentation rate, platelet count and white blood cell count, with fecal calprotectin as the gut-specific stool marker. CRP responds within hours and falls within days; ESR lags by weeks. All are supportive evidence rather than a diagnosis, and a single borderline value is typically repeated rather than acted on.

What are the early warning signs of IBD?

Patterns that should prompt a medical assessment include diarrhea lasting several weeks, blood or mucus in the stool, abdominal pain, unexplained weight loss, waking at night to open the bowels, and persistent fatigue, especially in a young adult. These symptoms have many causes and cannot confirm IBD on their own; only a doctor, usually with blood tests, stool tests and a scope, can make or exclude the diagnosis.

What are normal fecal calprotectin levels?

Most laboratories consider fecal calprotectin below about 50 micrograms per gram to be normal, but reference ranges vary between labs and assays, so results should be compared only within the same laboratory. For people already diagnosed with IBD, the STRIDE-II consensus uses a target range of roughly 100 to 250 micrograms per gram to indicate controlled inflammation. Your care team will interpret your number against your own history and trend.

What do CRP levels in Crohn's disease mean if they are normal?

A normal CRP in Crohn’s disease lowers the likelihood of active inflammation but does not exclude it. A meaningful proportion of people never raise CRP during flares because of genetic variation or because inflammation is confined to a short segment of bowel. If symptoms or calprotectin suggest activity despite a normal CRP, teams generally rely on stool testing, imaging or endoscopy rather than on the blood result.

How often is colonoscopy needed for ulcerative colitis?

Routine surveillance for precancerous change usually begins after roughly eight to ten years of colitis and then repeats at intervals of about one to five years, depending on disease extent, previous findings, family history and whether primary sclerosing cholangitis is present, according to guidance summarized by the Mayo Clinic. Disease limited to the rectum generally does not need surveillance. Separate scopes may be done to confirm healing after a flare or treatment change.

Can IBS raise fecal calprotectin?

No. Irritable bowel syndrome does not involve neutrophil inflammation of the gut lining, so it does not raise fecal calprotectin. That distinction is one of the test’s most useful properties: a person with IBD whose symptoms return but whose calprotectin stays normal may have an overlapping IBS-type problem rather than a flare, which points toward a different management approach and can spare an unnecessary scope.

Do I still need IBD monitoring if I feel completely well?

Yes, because inflammation can persist or return without symptoms, and silent inflammation is what leads to scarring, strictures and, in the colon, a higher long-term cancer risk. Monitoring when you feel well is precisely when stool markers are most valuable, since they can flag a problem before symptoms do. Tests also check that medicines are not affecting blood counts or liver function. Frequency is set by your treating team.

What is the difference between clinical remission and endoscopic remission?

Clinical remission means symptoms such as diarrhea, bleeding and pain have largely resolved. Endoscopic remission means the bowel lining looks healed when examined with a scope. The two often disagree: people can feel well while ulcers remain, or have symptoms with a healed lining. The STRIDE-II consensus makes endoscopic healing the long-term target because it is more consistently linked to fewer flares, hospital admissions and surgeries in observational studies.

References

• Inflammatory bowel disease (IBD) – NHS
• C-Reactive Protein (CRP) Test – MedlinePlus
• Colonoscopy – Cleveland Clinic

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.